Cancer Research CR Surrogates Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kobie, J. J.
Right arrow Articles by Akporiaye, E. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kobie, J. J.
Right arrow Articles by Akporiaye, E. T.
[Cancer Research 63, 1860-1864, April 15, 2003]
© 2003 American Association for Cancer Research

Immunology

Transforming Growth Factor ß Inhibits the Antigen-Presenting Functions and Antitumor Activity of Dendritic Cell Vaccines1

James J. Kobie, Rita S. Wu2, Robert A. Kurt, Sunming Lou, Miranda K. Adelman, Luke J. Whitesell, Lalitha V. Ramanathapuram, Carlos L. Arteaga and Emmanuel T. Akporiaye3

Departments of Microbiology and Immunology [J. J. K., R. S. W., S. L., M. K. A., L. V. R., E. T. A.] and Pediatrics [L. J. W.], University of Arizona, Tucson, Arizona 85724; Department of Biology, Lafayette College, Easton, Pennsylvania 18042 [R. A. K.]; and Departments of Medicine and Cancer Biology, Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37332 [C. L. A.]


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Dendritic cell (DC)-based vaccines have exhibited minimal effectiveness in treating established tumors, likely because of factors present in the tumor microenvironment. One such factor is transforming growth factor ß (TGF-ß), a cytokine that is produced by numerous tumor types and has been demonstrated to impair DC functions in vitro. We have evaluated the effect of TGF-ß on the immunostimulatory activities of DCs. We demonstrate that TGF-ß exposure inhibits the ability of DCs to present antigen, stimulate tumor-sensitized T lymphocytes, and migrate to draining lymph nodes. Neutralization of TGF-ß using the TGF-ß-neutralizing monoclonal antibody 2G7 enhanced the ability of DC vaccines to inhibit the growth of established 4T1 murine mammary tumors. Treatment of 4T1 tumors transduced with the antisense TGF-ß transgene (4T1-asT) with the combination of DC and 2G7 monoclonal antibody inhibited tumor growth and resulted in complete regression of tumors in 40% of the mice. These results demonstrate that neutralization of TGF-ß in tumor-bearing mice enhances the efficacy of DC-based vaccines.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
In recent years, DCs4 have become popular candidates in cancer vaccine development because of their crucial role in inducing T-cell responses. Upon antigen uptake, DCs residing in peripheral tissues internalize and process antigen and migrate to secondary lymphoid organs where they stimulate naïve T lymphocytes in the context of class I and class II MHC antigens (1) . The effectiveness of DCs as antigen-presenting cells provides the rationale for their use as cancer vaccines with the objective of inducing durable antitumor immune responses. In numerous rodent models, vaccines consisting of tumor antigen-pulsed DCs are effective in inducing CTL responses and providing protection against subsequent tumor challenge (2, 3, 4, 5) . In contrast, DC vaccines have been less effective in abrogating established tumors in mice (2, 3, 4, 5) and human cancer patients (6) . The insensitivity of established tumors to DC therapy is likely because of factors present within the tumor microenvironment that are inimical to the optimal induction of an antitumor immune response (7) . Examination of circulating and tumor-infiltrating DCs in tumor-bearing animals and in cancer patients has revealed that DCs are functionally impaired in their ability to induce T-cell responses (8, 9, 10, 11) . These deficits have been associated with down-regulation of MHC and costimulatory molecules (10 , 11) and tumor-induced apoptosis of DCs (12) .

One of the factors produced within the tumor microenvironment that might interfere with DC functions is TGF-ß. TGF-ß is a pleiotropic cytokine produced by cancer cells of different histological types (13, 14, 15, 16) . Among the plethora of immunosuppressive effects of TGF-ß (17) is the capacity to interfere with several DC functions. These include down-regulation of cell surface MHC antigens, costimulatory molecules, chemokine receptors, as well as impairment of in vitro chemotaxis (18, 19, 20) .

Although the in vitro effects of TGF-ß on DCs are relatively well known, the impact of TGF-ß on the ability of DCs to migrate to secondary lymphoid organs and induce specific antitumor T-cell responses in vivo remains to be determined. In this study, we demonstrate that TGF-ß inhibits DC migration to DLN and diminishes their capacity to stimulate IFN-{gamma} secretion by tumor-sensitized T lymphocytes. Most importantly, we show that the combined use of antisense TGF-ß gene transfer plus TGF-ß-neutralizing antibody increases the efficacy of DC vaccines in treating established TGF-ß-secreting 4T1 mammary tumors.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Animals.
Six-week-old female BALB/c and C57BL/6 (B6) mice were purchased from The Harlan Laboratory (Indianapolis, IN). Six-week-old female BALB/c-TgN (DO11.10) 10 Loh mice were purchased from The Jackson Laboratory (Bar Harbor, ME). All mice were housed at the University of Arizona Animal Facilities in accordance with the Principles of Animal Care (NIH publication no. 85-23, revised 1985).

Tumors.
4T1 murine mammary tumor cells were kindly provided by Dr. Fred Miller (Michigan Cancer Foundation, Detroit, MI) and maintained as described previously (21) .

TGF-ß-neutralizing Antibody (2G7).
The 2G7 mouse IgG1 mAb was generated after immunization of BALB/c mice with recombinant human TGF-ß1. 2G7 neutralized the growth inhibitory activity of TGF-ß1, TGF-ß2, and TGF-ß3 on Mv1Lu epithelial cells (22) .

Generation of DCs and TGF-ß Treatment.
Bone marrow cells were harvested from flushed marrow cavities of femurs and tibiae under aseptic conditions and cultured with 100 units/ml granulocyte macrophage colony-stimulating factor and 100 units/ml interleukin 4 (Peprotech, Rocky Hill, NJ) at 106 cells/ml in complete media (RPMI 1640 containing 10% heat-inactivated FBS, 0.1 mM nonessential amino acids, 1 µM sodium pyruvate, 2 mM L-glutamine, 100 µg/ml streptomycin, 100 units/ml penicillin, 0.5 µg/ml fungizone, and 5 x 10-5 M 2-mercaptoethanol). Cytokines were replenished on day 4. On day 6 of culture, DCs were collected and cultured at 106 cells/ml with granulocyte macrophage colony-stimulating factor and interleukin 4 with or without the addition of 10 ng/ml of recombinant human TGF-ß1 (R&D Systems, Minneapolis, MN) for 6 days. DCs were matured with 200 units/ml of TNF-{alpha} (Peprotech) for 48 h.

FACS Analysis.
All antibodies used were purchased from Caltag Laboratories (Burlingame, CA) unless otherwise noted. For analysis of DCs, samples were stained with PE-conjugated anti-CD11c (BD PharMingen, San Diego, CA), FITC-conjugated anti-I-Ad (BD PharMingen), PE-conjugated anti-B7.1 (CD80), FITC-conjugated anti-B7.2 (CD86), or PE-conjugated anti-CD40. T cells were stained with PE-conjugated anti-CD3, FITC-conjugated anti-B220, PE-conjugated anti-CD8, or FITC-conjugated anti-CD4. Cells were analyzed using a FACStarPLUS flow cytometer (Becton Dickinson Immunocytometry Systems, San Jose, CA).

Induction of Allogeneic Mixed Lymphocyte Reactions.
Spleen cells from B6 mice were harvested and enriched for CD3-positive cells using a T-cell enrichment column (R&D Systems). Cells were 80–95% CD3 positive as determined by FACS analysis. Varying numbers of DCs were incubated with 2 x 105 T lymphocytes for 5 days in 96-well tissue culture plates (Sarstedt, Newton, NC) with the addition of 1 µCi of [3H]thymidine (Perkin-Elmer Life Sciences, Boston, MA) for the final 18 h of culture.

OVA Peptide Presentation Assay.
Spleen cells from DO11.10 OVA T cell receptor transgenic mice were enriched for CD3 positive cells as described above. Varying numbers of DCs were incubated with 2 x 105 T lymphocytes in the presence of 1 µM of OVA peptide (ISQAVHAAHAEINEAGR; United Biochemical Research, Seattle, WA) in 96-well tissue culture plates for 5 days with the addition of 1 µCi of [3H]thymidine for the final 18 h of culture.

Endocytosis and Phagocytosis Assays.
Endocytosis and phagocytosis assays were performed using modifications of previously described procedures (23) . Endocytosis was measured by incubating 2 x 105 DC with 400 µg of FITC-conjugated dextran beads, 40,000 MW (Molecular Probes, Eugene, OR) for 30 min at 4°C or 37°C. Phagocytosis was measured by incubating DCs with FITC-conjugated Escherichia coli (Molecular Probes) at a ratio of 100 E. coli particles to 1 DC for 60 min at 4°C or 37°C. After incubation, cells were washed extensively with PBS containing 0.5% bovine albumin and 0.1% sodium azide and analyzed by flow cytometry.

Stimulation of Tumor-sensitized T Lymphocytes.
Bone marrow-derived DCs were pulsed with 4T1 tumor cell lysate at a ratio of 3 tumor cell equivalents/DC for 24 h in the presence or absence of 10 ng/ml TGF-ß1. DCs were then matured with 20 ng/ml TNF-{alpha} in the presence or absence of 10 ng/ml TGF-ß1. Splenic T lymphocytes were purified from mice bearing 14 day 4T1 tumors as indicated above. Ten thousand DCs were incubated with 2 x 105 splenic T lymphocytes in 96-well tissue culture plates for 5 days with the addition of 1 µCi of [3H]thymidine for the final 18 h of culture. One million tumor DLN cells from mice bearing 14 day 4T1 tumors were incubated with 2.5 x 105 DCs for 48 h, and IFN-{gamma} production was evaluated by ELISA (R&D Systems).

In Vivo Migration Assay.
Bone marrow-derived DCs were matured with 200 units/ml TNF-{alpha} with or without 10 ng/ml TGF-ß1 for 48 h. DCs were labeled with 10 µM PKH-67L, green fluorescent dye (Sigma, St. Louis, MO) as described previously (20) . Naive mice received s.c. injections in the right flank with 5–8 x 106 DCs. Forty-eight h after injection, mice were sacrificed, and inguinal lymph nodes were harvested and disaggregated. Lymph node cells were centrifuged (Shandon, Pittsburgh, PA) onto glass slides at 700 rpm for 4 min. The slides were fixed with 4% paraformaldehyde and stained with a propidium iodide/RNase solution (Phoenix Flow Systems, San Diego, CA). Slides were analyzed using a laser scanning cytometer (CompuCyte, Cambridge, MA). Detection and contouring of cells was keyed by propidium iodide signal, whereas DCs were identified by their green fluorescence signal; 35,000 propidium iodide events were analyzed from each treatment group/experiment. The identity of each DC detected during scanning was confirmed visually by direct microscopic observation using the instrument’s relocation function.

In Vitro Chemotaxis Assay.
Bone marrow-derived DCs were matured with TNF-{alpha} in the presence or absence of TGF-ß1 for 48 h as indicated above. An in vitro chemotaxis assay was performed as described previously (24) . SLC (Peprotech) and MIP-3ß (R&D Systems) were diluted with serum-free media to a final volume of 600 µl of 100 ng/ml chemokine and added to 24-well tissue culture plates (Corning Costar, Cambridge, MA). Transwell culture inserts (Corning Costar) with 6.5-mm diameter and 5.0-µm pore-size were inserted into each well, and DCs (4 x 105 cells/each well) were added to the top chamber in serum-free media at a final volume of 100 µl. After the plates were incubated at 37°C in 5% CO2 for 4 h, the cells in the bottom chamber were recovered, the migrating cells were counted, and an aliquot was stained with anti-CD11c mAbs to be analyzed by FACS. Controls included wells with chemokine in both the top and bottom chambers. The number of migrated cells was determined by subtracting the number of migrated cells in control wells from the number of migrated cells in experimental wells.

Treatment of Established Tumors.
Six-week-old BALB/c mice were orthotopically injected with 104 4T1-N or 4T1-asT tumor cells into the mammary gland. DCs were pulsed with 4T1 tumor cell lysate at a ratio of 3 tumor cell equivalents/dendritic cell for 24 h. After pulsing, DCs were matured with 200 units/ml TNF-{alpha} for 48 h. Mice were injected i.t. with 1.5 x 106 tumor cell lysate-pulsed, matured DCs in 50 µl of PBS on day 15 when tumors were palpable. Vaccination was repeated on days 20 and 25. Two h before each vaccination, mice received i.p. injections of 300 µg of 2G7 mAb. In combination with DCs or alone, mice received 100 µg of 2G7 mAb i.t. Primary tumors were measured as reported previously (21) . Mice exhibiting complete tumor regression were challenged with 10-fold more 4T1 tumor cells (105) and monitored for tumor growth.

Statistical Analysis.
For all analyses, student t tests were performed using Prism software (GraphPad, San Diego, CA). Ps of <0.05 were considered to indicate significant differences between data sets.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Antigen Uptake and Presentation by DCs.
Before evaluating the effect of TGF-ß in vivo, we evaluated its effects on several DC functions in vitro. Treatment of DCs with TGF-ß caused a significant (P < 0.05) decrease in the levels of B7.1 and CD40 (Fig. 1A)Citation , as well as in the percentage of cells expressing CD40 (Fig. 1B)Citation . Next, we evaluated the ability of DCs to endocytose dextran particles and phagocytose E. coli particles after TGF-ß treatment. TGF-ß exposure inhibited the endoocytic and phagocytic capacities of DCs by 58% and 87%, respectively (Fig. 1C), a pattern that was observed in all three experiments conducted. To evaluate the effect of TGF-ß exposure on antigen presentation, mixed lymphocyte reactions were performed. Stimulation of allogeneic T lymphocytes (Fig. 1D)Citation and presentation of OVA peptide (Fig. 1E)Citation by DCs was significantly (P < 0.05) suppressed after TGF-ß exposure. These results demonstrate that TGF-ß inhibits the uptake and presentation of antigens by DCs.



View larger version (25K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Effect of TGF-ß exposure on DC functions in vitro. DCs were incubated in the absence or presence of 10 ng/ml TGF-ß for 6 days. Cytokines were replenished every 2 days. A and B, DCs were stained with anti-CD11c, anti-I-Ad, anti-B7.1, anti-B7.2, and anti-CD40 antibodies and analyzed by flow cytometry. The results are mean ± SE of three independent experiments. C, DCs were incubated with FITC-conjugated dextran particles or FITC-conjugated E. coli particles at 4°C or 37°C, fixed, and analyzed by flow cytometry. Values represent mean fluorescence intensity (MFI) at 37°C minus 4°C. D, DCs were incubated with 2 x 105 splenic T cells isolated from C57/BL6 mice for 5 days with the addition of [3H]thymidine for the last 18 h of culture. Values represent mean ± SE of six replicates. E, DCs were collected and incubated with 2 x 105 splenic T cells isolated from BALB/c-TgN (DO11.10) 10 Loh mice in the presence of OVA peptide for 5 days with the addition of [3H]thymidine for the last 18 h of culture. Values represent mean ± SE of four replicates. Results are from one representative experiment of three independent experiments. * refers to statistical significance between groups (P < 0.05).

 
Induction of Tumor-sensitized T Lymphocytes.
Observing that TGF-ß inhibits the antigen uptake and presentation capacities of DCs, we evaluated its effect on the stimulation of tumor-sensitized T lymphocytes by tumor cell lysate-pulsed immature and mature DCs. TGF-ß-treated mature DCs were significantly less effective (P = 0.0002) than untreated mature DCs at stimulating the proliferation of tumor-sensitized T lymphocytes (Fig. 2A)Citation . The ability of immature and mature DCs to stimulate IFN-{gamma} production by tumor-sensitized lymphocytes was also significantly inhibited (P < 0.0001, P = 0.0003) by 60 and 22%, respectively, after TGF-ß exposure. Taken together, these data demonstrate that TGF-ß exposure reduces the ability of DCs to stimulate antitumor immune responses.



View larger version (20K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Stimulation of tumor-sensitized T lymphocytes. DCs were pulsed with tumor cell lysate for 48 h in the presence or absence of 10 ng/ml TGF-ß (immature), then cultured in TNF-{alpha} in the presence or absence of TGF-ß for 48 h (mature). A, ten thousand DCs were incubated with 2 x 105 splenic T cells isolated from mice bearing 4T1 tumors for 5 days, and [3H]thymidine was added for the last 18 h of culture. B, one million T cells isolated from lymph nodes draining 4T1 tumors were incubated with 2.5 x 105 DCs for 48 h. After incubation, supernatant was analyzed for IFN-{gamma} production. Numbers are mean ± SE of triplicate samples. Results are from one representative experiment of two independent experiments. * refers to statistical significance between groups (P < 0.05).

 
In Vivo Migration and In Vitro Chemotaxis.
Because migration of DCs to secondary lymphoid organs is necessary for T-cell priming (25) , we assessed the effect of TGF-ß treatment on the ability of mature DC to migrate to DLNs. For this purpose, TGF-ß-treated DCs were labeled with PKH-67 and injected s.c. into the hind flank of mice. Forty-eight h later, draining inguinal lymph nodes were harvested, and infiltrating DCs were enumerated by scanning laser cytometry. TGF-ß treatment resulted in a decrease in migration of mature DCs to the DLNs (Table 1)Citation . This was a significant (P < 0.05) trend observed over four independent experiments. To determine the mechanism responsible for decreased migration of mature DCs, in vitro chemotaxis toward SLC and MIP-3ß was evaluated. DCs migrating to the bottom chambers were recovered and analyzed by flow cytometry for CD11c expression. No significant difference in CD11c expression was observed between untreated and TGF-ß-treated DCs (data not shown). TGF-ß treatment caused reduced migration of DC toward both SLC and MIP-3ß, however, only migration toward MIP-3ß was significantly decreased (P < 0.05; Fig. 3Citation ).


View this table:
[in this window]
[in a new window]

  		Table 1 Effect of TGF-ß on in vivo migration

 


View larger version (16K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Effect of TGF-ß on in vitro chemotaxis. DCs were added to the upper chamber of a transwell migration chamber and evaluated for chemotactic migration. Cells migrating to the bottom chamber were recovered and analyzed by flow cytometry for CD11c expression. The results are mean ± SE of three independent experiments. * refers to statistical significance between groups (P < 0.05).

 
Treatment of Established Tumors with DCs and Neutralizing TGF-ß Antibody.
The impairment of critical DC functions, including antigen uptake and antigen presentation, tumor-specific T lymphocyte stimulation, and in vivo migration by TGF-ß, suggested that inhibition of TGF-ß production in tumor-bearing animals may improve the efficacy of DC vaccines. To test this possibility, TGF-ß production was suppressed by transfer of an antisense TGF-ß transgene into 4T1 cells (4T1-asT) as described previously (21) . Expression of the transgene resulted in >90% inhibition of TGF-ß production (0.083 ± 0.003 ng/ml in 4T1-asT compared with 1.244 ± 0.188 ng/ml in mock-transduced cells (4T1-N). Treatment of 4T1-asT tumors with 2G7 mAb alone or DCs plus 2G7 mAb significantly inhibited (P < 0.05) tumor growth compared with 4T1-asT tumors treated with DCs alone (Fig. 4)Citation . Furthermore, complete tumor regression occurred in 40% (two of five) of 4T1-asT-tumor-bearing mice that were treated with DCs plus 2G7 mAb (Fig. 4)Citation . Similarly, mock-transduced (4T1-N) tumors responded significantly better (P < 0.05) to treatment with DCs plus 2G7 mAb as compared with treatment with DCs alone; however, tumor growth inhibition in this group was inferior to that observed in animals bearing 4T1-asT tumors. (Fig. 4)Citation . Tumor growth was not affected by treatment with isotype control (IgG) antibody (data not shown). To determine whether the mice that exhibited complete tumor regression had developed long-term immunity, they were rechallenged with parental 4T1 tumor cells. These mice failed to develop tumors (zero of two); however, all control naive mice challenged with tumor cells developed tumors (three of three). These data suggest that neutralization of TGF-ß in mice bearing TGF-ß-secreting tumors enhances the effectiveness of DC vaccines in treating established tumors.



View larger version (12K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. Treatment of established tumors. BALB/c mice with established 4T1-N (mock transfected) and 4T1-asT (transfected with antisense TGF-ß gene) tumors were vaccinated intratumorally on days 15, 20, and 25 with 1.5 x 106 tumor cell lysate-pulsed mature DCs alone or in combination with 100 µg i.t and 300 µg i.p of 2G7, TGF-ß-neutralizing antibody. Control mice were treated with 2G7 antibody alone. Mice were monitored for tumor growth. Graph represents mean tumor volume ± SE of 5 mice. * indicates significant (P < 0.05) difference as compared with mice treated with DC alone on day 40.

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
In this study, we evaluated the impact of TGF-ß on in vivo migration and immunostimulatory activities of DCs. Our results demonstrate that TGF-ß treatment diminishes the ability of DC to migrate to secondary lymphoid organs and to induce T-cell responses. Most importantly, suppression of tumor-derived TGF-ß by antisense TGF-ß gene transfer plus neutralization of secreted TGF-ß with anti-TGF-ß mAb significantly improved the antitumor activity of intratumorally injected tumor cell lysate-pulsed DCs. Previous studies have demonstrated that suppression of TGF-ß by antisense gene transfer (13 , 21 , 26) or abrogation of TGF-ß using neutralizing antibody (27 , 28) increases tumor immunogenicity, leading to tumor growth inhibition or rejection. To our knowledge, this is the first study to evaluate the impact of both approaches simultaneously on DCs in controlling established tumors. The finding that the antitumor effect was most evident when antisense TGF-ß-expressing tumors were treated with DCs plus anti-TGF-ß mAb directly implicates tumor-derived TGF-ß in tumor progression. In our study, TGF-ß within the tumor milieu could be promoting tumor growth by interfering with the antigen-presenting and effector functions of DCs at the tumor site, as well as preventing the emigration of injected DCs to DLNs to activate naïve tumor-specific T lymphocytes. The former possibility is supported by the recent findings by Kirk et al. (29) who suggested that migration of i.t. injected DCs to DLNs is not required for the induction of an antitumor response. Using SLC gene-modified DCs, they demonstrated comparable tumor growth inhibition in normal mice and lymphotoxin a-/- mice lacking peripheral lymph nodes (29) . The latter possibility is supported by the decreased chemotactic response of TGF-ß-treated DCs to MIP-3ß and SLC observed in our study. These chemokines produced in the lymph nodes recruit DCs via their interaction with the chemokine receptor, CCR7 (20 , 30) . A possible explanation is that CCR7 gene expression is inhibited in DC by TGF-ß treatment as has been reported by others (19 , 20) .

As with previously published studies (29 , 31 , 32) , only a minute fraction (<1%) of s.c. injected DCs in our study migrated to DLNs. It is yet to be determined if these lymph node-infiltrating DCs represent a unique subpopulation capable of singularly stimulating the antitumor response or require the participation of endogenous DCs to achieve this goal. In the setting of DC vaccination to prevent or treat inaccessible micrometastases, it is desirable that adoptively transferred DCs are able to migrate to secondary lymphoid organs to stimulate naïve T lymphocytes. Thus this LN-infiltrating, ex vivo manipulated DC population needs to be more actively studied.

In summary, this study demonstrates the potential usefulness of a combined therapeutic approach to eliminate immunosuppressive tumor-derived factors to improve the effectiveness of DC-based vaccines.


   ACKNOWLEDGMENTS
 
We thank Vivian Mack for technical assistance and Barbara Carolus for flow cytometric analysis.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by NIH Grants 1 RO1 CA9411-01 and DAMD 170010128 and DAMD 17010126 from the Department of Defense/United States Army. Back

2 Present address: Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY 10021. Back

3 To whom requests for reprints should be addressed, at The University of Arizona, Department of Microbiology and Immunology, 1501 North Campbell Avenue, Tucson, AZ 85724. E-mail: akporiay{at}u.arizona.edu Back

4 The abbreviations used are: DC, dendritic cell; DLN, draining lymph node; mAb, monoclonal antibody; FBS, fetal bovine serum; TGF-ß, transforming growth factor ß; TNF-{alpha}, tumor necrosis factor {alpha}; FACS, fluorescence-activated cell sorter; PE, r-phycoerythrin; OVA, ovalbumin; SLC, secondary lymphoid chemokine; MIP-3ß, macrophage inflammatory protein 3ß. Back

Received 5/28/02. Accepted 2/18/03.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Steinman R. M. The dendritic cell system and its role in immunogenicity. Ann. Rev. Immunol., 9: 271-296, 1991.[Medline]
  2. Gabrilovich D. I., Nadaf S., Corak J., Berzofsky J. A., Carbone D. P. Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors. Cell Immunol., 170: 111-119, 1996.[Medline]
  3. Coveney E., Wheatley G. H., III, Lyerly H. K. Active immunization using dendritic cells mixed with tumor cells inhibits the growth of primary breast cancer. Surgery (St. Louis), 122: 228-234, 1997.[Medline]
  4. DeMatos P., Abdel-Wahab Z., Vervaert C., Hester D., Seigler H. Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice. J. Surg., 68: 79-91, 1998.
  5. Fields R. C., Shimizu K., Mule J. J. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc. Natl. Acad. Sci. USA, 95: 9482-9487, 1998.[Abstract/Free Full Text]
  6. Morse M. A., Lyerly H. K. Clinical applications of dendritic cell vaccines. Curr. Opin. Mol. Ther., 2: 20-28, 2000.[Medline]
  7. Marincola F. M., Jaffe E. M., Hicklin D. J., Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol., 74: 181-273, 2000.[Medline]
  8. Chaux P., Moutet M., Faivre J., Martin F., Martin M. Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7–1 and B7–2 costimulatory molecules of the T-cell activation. Lab. Investig., 74: 975-983, 1996.[Medline]
  9. Gabrilovich D. I., Ciernik I. F., Carbone D. P. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell. Immunol., 170: 101-110, 1996.[Medline]
  10. Enk A. H., Jonuleit H., Saloga J., Knop J. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int. J. Cancer, 73: 309-316, 1997.[Medline]
  11. Gabrilovich D. I., Corak J., Ciernik I. F., Kavanaugh D., Carbone D. P. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin. Cancer Res., 3: 483-490, 1997.[Abstract]
  12. Esche C., Lokshin A., Shurin G. V., Gastman B. R., Rabinowich H., Watkins S. C., Lotze M. T., Shurin M. R. Tumor’s other immune targets: dendritic cells. J. Leukoc. Biol., 66: 336-344, 1999.[Abstract]
  13. Stampfer M. R., Yaswen P., Alhadeff M., Hosoda J. TGF-ß induction of extracellular matrix associated proteins in normal and transformed human mammary epithelial cells in culture is independent of growth effects. J. Cell. Physiol., 155: 210-221, 1993.[Medline]
  14. Fischer J. R., Darjes H., Lahm H., Schindel M., Drings P., Krammer P. H. Constitutive secretion of bioactive transforming growth factor ß1 by small cell lung cancer cell lines. Eur. J. Cancer, 30A: 2125-2129, 1994.
  15. Rodeck U., Bossler A., Graeven U., Fox F. E., Nowell P. C., Knabbe C., Kari C. Transforming growth factor ß production and responsiveness in normal human melanocytes and melanoma cells. Cancer Res., 2: 575-581, 1994.
  16. Park J. A., Kurt R. A., Schluter S. F., Hersh E. M., Akporiaye E. T. Expression of an antisense transforming growth factor ß1 transgene reduces tumorigenicity of EMT6 mammary tumor cells. Cancer Gene Ther., 4: 42-50, 1997.[Medline]
  17. De Visser K., Kast W. M. Effects of TGF-ß on the immune system: implications for cancer immunotherapy. Leukemia (Baltimore), 13: 1188-1199, 1999.[Medline]
  18. Ogata M., Zhang Y., Wang Y., Itakura M., Zhang Y. Y., Harada A., Hashimoto S., Matsushima K. Chemotactic response toward chemokines and its regulation by transforming growth factor ß1 of murine bone marrow hematopoietic progenitor cell-derived different subsets of dendritic cells. Blood, 93: 3225-3232, 1999.[Abstract/Free Full Text]
  19. Sato K., Kawasaki H., Nagayama H., Enomoto M., Morimoto C., Tadokoro K., Juji T., Takahashi T. A. TGF-ß1 reciprocally controls chemotaxis of human peripheral blood monocyte-derived dendritic cells via chemokine receptors. J. Immunol., 164: 2285-2295, 2000.[Abstract/Free Full Text]
  20. Takayama T., Morelli A. E., Onai N., Hirao M., Matsushima K., Tahara H., Thomson A. W. Mammalian and viral IL-10 enhance C-C chemokine receptor 5 but down-regulate C-C chemokine receptor 7 expression by myeloid dendritic cells: impact on chemotactic responses and in vivo homing ability. J. Immunol., 166: 7136-7143, 2001.[Abstract/Free Full Text]
  21. Wu R. S., Kobie J. J., Besselsen D. G., Fong T. C., Mack V. D., McEarchern J. A., Akporiaye E. T. Comparative analysis of IFN-{gamma}, B7.1 and antisense TGF-ß gene transfer on the tumorigenicity of a poorly immunogenic metastatic mammary carcinoma. Cancer Immunol. Immunother., 50: 229-240, 2001.[Medline]
  22. Lucas C., Bald L. N., Fendly B. M., Mora-Worms M., Figari I. S., Patzer E. J., Palladino M. A. The autocrine production of transforming growth factor-ß1 during lymphocyte activation. A study with a monoclonal antibody-based ELISA. J. Immunol., 145: 1415-1422, 1990.[Abstract]
  23. Labeur M. S., Roters B., Pers B., Mehling A., Luger T. A., Schwarz T., Grabbe S. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J. Immunol., 162: 168-175, 1999.[Abstract/Free Full Text]
  24. Hirao M., Onai N., Hiroishi K., Watkins S. C., Matsushima K., Robbins P. D., Lotze M. T., Tahara H. CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes. Cancer Res., 60: 2209-2217, 2000.[Abstract/Free Full Text]
  25. Banchereau J., Steinman R. Dendritic cells and the control of immunity. Nature (Lond.), 392: 245-252, 1998.[Medline]
  26. Fakhrai H., Dorigo O., Shawler D. L., Lin H., Mercola D., Black K. L., Royston I., Sobol R. E. Eradication of established intracranial rat gliomas by transforming growth factor ß antisense gene therapy. Proc. Natl. Acad. Sci. USA, 93: 2909-2914, 1996.[Abstract/Free Full Text]
  27. Arteaga C. L., Hurd S. D., Winnier A. R., Johnson M. D., Fendly B. M., Forbes J. T. Anti-transforming growth factor (TGF)-ß antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. J. Clin. Investig., 92: 2568-2576, 1993.
  28. Wojtowicz-Praga S., Verma U. N., Wakefield L., Esteban J. M., Hartmann D., Mazumder A., Verma U. M. Modulation of B16 melanoma growth and metastasis by anti-transforming growth factor ß antibody and interleukin-2. J. Immunother. Emphasis Tumor Immunol., 19: 169-175, 1996.[Medline]
  29. Kirk C. J., Hartogan-O’Conner C. D., Mule J. J. The dynamics of the T-cell antitumor response: chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally. Cancer Res., 61: 8794-8802, 2001.[Abstract/Free Full Text]
  30. Rossi D., Zlotnik A. The biology of chemokines and their receptors. Annu. Rev. Immunol., 18: 217-242, 2000.[Medline]
  31. Eggert A. A., Schreurs M. W., Boerman O. C., Oyen W. J., de Boer A. J., Punt C. J., Figdor C. G., Adema G. J. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res., 59: 3340-3345, 1999.[Abstract/Free Full Text]
  32. Lappin M. B., Weiss J. M., Delattre V., Mai B., Dittmar H., Maier C., Manke K., Grabbe S., Martin S., Simon J. C. Analysis of mouse dendritic cell migration in vivo upon subcutaneous and intravenous injection. Immunology, 98: 181-188, 1999.[Medline]



This article has been cited by other articles:


Home page
 J. Immunol.Home page
D. S. Gregerson, N. D. Heuss, U. Lehmann, and S. W. McPherson
Peripheral Induction of Tolerance by Retinal Antigen Expression
J. Immunol., July 15, 2009; 183(2): 814 - 822.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Fujita, K. Teramoto, Y. Ozaki, J. Hanaoka, N. Tezuka, Y. Itoh, T. Asai, S. Fujino, K. Kontani, and K. Ogasawara
Inhibition of Transforming Growth Factor-{beta}-Mediated Immunosuppression in Tumor-Draining Lymph Nodes Augments Antitumor Responses by Various Immunologic Cell Types
Cancer Res., June 15, 2009; 69(12): 5142 - 5150.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
M. P. RAUSCH, T. HAHN, L. RAMANATHAPURAM, D. BRADLEY-DUNLOP, D. MAHADEVAN, M. E. MERCADO-PIMENTEL, R. B. RUNYAN, D. G. BESSELSEN, X. ZHANG, H.-K. CHEUNG, et al.
An Orally Active Small Molecule TGF-{beta} Receptor I Antagonist Inhibits the Growth of Metastatic Murine Breast Cancer
Anticancer Res, June 1, 2009; 29(6): 2099 - 2109.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Cohen, J. Haimovich, and N. Hollander
Dendritic Cell-Based Therapeutic Vaccination against Myeloma: Vaccine Formulation Determines Efficacy against Light Chain Myeloma
J. Immunol., February 1, 2009; 182(3): 1667 - 1673.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Kim, G. Buchlis, Z. G. Fridlender, J. Sun, V. Kapoor, G. Cheng, A. Haas, H. K. Cheung, X. Zhang, M. Corbley, et al.
Systemic Blockade of Transforming Growth Factor-{beta} Signaling Augments the Efficacy of Immunogene Therapy
Cancer Res., December 15, 2008; 68(24): 10247 - 10256.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Zhang, B. E. Berndt, J.-J. Chen, and J. Y. Kao
Expression of a Soluble TGF-{beta} Receptor by Tumor Cells Enhances Dendritic Cell/Tumor Fusion Vaccine Efficacy
J. Immunol., September 1, 2008; 181(5): 3690 - 3697.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. A. Cohen, G. K. Koski, B. J. Czerniecki, K. D. Bunting, X.-Y. Fu, Z. Wang, W.-J. Zhang, C. S. Carter, M. Awad, C. A. Distel, et al.
STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34pos cells into tumor-competent dendritic cells
Blood, September 1, 2008; 112(5): 1832 - 1843.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
B. A Teicher, J. M Yingling, and J. M McPherson
TGF{beta} Blockade as Anticancer Therapy
Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 71 - 81.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. A. Teicher
Transforming Growth Factor-{beta} and the Immune Response to Malignant Disease
Clin. Cancer Res., November 1, 2007; 13(21): 6247 - 6251.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
K. L. Kislin, M. T. Marron, G. Li, M. W. Graner, and E. Katsanis
Chaperone-rich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR-ABL positive leukemia
FASEB J, July 1, 2007; 21(9): 2173 - 2184.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. M. Seavey and T. R. Mosmann
Paternal Antigen-Bearing Cells Transferred during Insemination Do Not Stimulate Anti-Paternal CD8+ T Cells: Role of Estradiol in Locally Inhibiting CD8+ T Cell Responses
J. Immunol., December 1, 2006; 177(11): 7567 - 7578.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
R. S. Kornbluth and G. W. Stone
Immunostimulatory combinations: designing the next generation of vaccine adjuvants
J. Leukoc. Biol., November 1, 2006; 80(5): 1084 - 1102.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. Bellone, A. Carbone, C. Smirne, T. Scirelli, A. Buffolino, A. Novarino, A. Stacchini, O. Bertetto, G. Palestro, C. Sorio, et al.
Cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells.
J. Immunol., September 1, 2006; 177(5): 3448 - 3460.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Ge, V. Rajeev, P. Ray, E. Lattime, S. Rittling, S. Medicherla, A. Protter, A. Murphy, J. Chakravarty, S. Dugar, et al.
Inhibition of Growth and Metastasis of Mouse Mammary Carcinoma by Selective Inhibitor of Transforming Growth Factor-{beta} Type I Receptor Kinase In vivo.
Clin. Cancer Res., July 15, 2006; 12(14): 4315 - 4330.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. S. von Bergwelt-Baildon, A. Popov, T. Saric, J. Chemnitz, S. Classen, M. S. Stoffel, F. Fiore, U. Roth, M. Beyer, S. Debey, et al.
CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition
Blood, July 1, 2006; 108(1): 228 - 237.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J.-S. Nam, A. M. Suchar, M.-J. Kang, C. H. Stuelten, B. Tang, A. M. Michalowska, L. W. Fisher, N. S. Fedarko, A. Jain, J. Pinkas, et al.
Bone Sialoprotein Mediates the Tumor Cell-Targeted Prometastatic Activity of Transforming Growth Factor {beta} in a Mouse Model of Breast Cancer.
Cancer Res., June 15, 2006; 66(12): 6327 - 6335.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
M.-L. Cheng, H.-W. Chen, J.-P. Tsai, Y.-P. Lee, Y.-C. Shih, C.-M. Chang, and C.-C. Ting
Clonal restriction of the expansion of antigen-specific CD8+ memory T cells by transforming growth factor-{beta}
J. Leukoc. Biol., May 1, 2006; 79(5): 1033 - 1042.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Ito, Y. Minamiya, H. Kawai, S. Saito, H. Saito, T. Nakagawa, K. Imai, M. Hirokawa, and J.-i. Ogawa
Tumor-Derived TGFbeta-1 Induces Dendritic Cell Apoptosis in the Sentinel Lymph Node
J. Immunol., May 1, 2006; 176(9): 5637 - 5643.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. Ebata, Y. Shimizu, Y. Nakayama, M. Minemura, J. Murakami, T. Kato, S. Yasumura, T. Takahara, T. Sugiyama, and S. Saito
Immature NK Cells Suppress Dendritic Cell Functions during the Development of Leukemia in a Mouse Model
J. Immunol., April 1, 2006; 176(7): 4113 - 4124.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S.-C. Yang, R. K. Batra, S. Hillinger, K. L. Reckamp, R. M. Strieter, S. M. Dubinett, and S. Sharma
Intrapulmonary Administration of CCL21 Gene-Modified Dendritic Cells Reduces Tumor Burden in Spontaneous Murine Bronchoalveolar Cell Carcinoma.
Cancer Res., March 15, 2006; 66(6): 3205 - 3213.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Rughetti, I. Pellicciotta, M. Biffoni, M. Backstrom, T. Link, E. P. Bennet, H. Clausen, T. Noll, G. C. Hansson, J. M. Burchell, et al.
Recombinant Tumor-Associated MUC1 Glycoprotein Impairs the Differentiation and Function of Dendritic Cells
J. Immunol., June 15, 2005; 174(12): 7764 - 7772.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. Esplugues, J. Vega-Ramos, D. Cartoixa, B. N. Vazquez, I. Salaet, P. Engel, and P. Lauzurica
Induction of tumor NK-cell immunity by anti-CD69 antibody therapy
Blood, June 1, 2005; 105(11): 4399 - 4406.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. A. Lyakh, M. Sanford, S. Chekol, H. A. Young, and A. B. Roberts
TGF-{beta} and Vitamin D3 Utilize Distinct Pathways to Suppress IL-12 Production and Modulate Rapid Differentiation of Human Monocytes into CD83+ Dendritic Cells
J. Immunol., February 15, 2005; 174(4): 2061 - 2070.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Suzuki, D. Wakita, K. Chamoto, Y. Narita, T. Tsuji, T. Takeshima, H. Gyobu, Y. Kawarada, S. Kondo, S. Akira, et al.
Liposome-Encapsulated CpG Oligodeoxynucleotides as a Potent Adjuvant for Inducing Type 1 Innate Immunity
Cancer Res., December 1, 2004; 64(23): 8754 - 8760.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Jinushi, T. Takehara, T. Tatsumi, T. Kanto, T. Miyagi, T. Suzuki, Y. Kanazawa, N. Hiramatsu, and N. Hayashi
Negative Regulation of NK Cell Activities by Inhibitory Receptor CD94/NKG2A Leads to Altered NK Cell-Induced Modulation of Dendritic Cell Functions in Chronic Hepatitis C Virus Infection
J. Immunol., November 15, 2004; 173(10): 6072 - 6081.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
X. Chen, K. Doffek, S. L. Sugg, and J. Shilyansky
Phosphatidylserine Regulates the Maturation of Human Dendritic Cells
J. Immunol., September 1, 2004; 173(5): 2985 - 2994.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Suzuki, V. Kapoor, H.-K. Cheung, L. E. Ling, P. A. DeLong, L. R. Kaiser, and S. M. Albelda
Soluble Type II Transforming Growth Factor-{beta} Receptor Inhibits Established Murine Malignant Mesothelioma Tumor Growth by Augmenting Host Antitumor Immunity
Clin. Cancer Res., September 1, 2004; 10(17): 5907 - 5918.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. H. Um, C. Mulhall, A. Alisa, A. R. Ives, J. Karani, R. Williams, A. Bertoletti, and S. Behboudi
{alpha}-Fetoprotein Impairs APC Function and Induces Their Apoptosis
J. Immunol., August 1, 2004; 173(3): 1772 - 1778.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. S. Gregerson, T. N. Sam, and S. W. McPherson
The Antigen-Presenting Activity of Fresh, Adult Parenchymal Microglia and Perivascular Cells from Retina
J. Immunol., June 1, 2004; 172(11): 6587 - 6597.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S.-C. Yang, S. Hillinger, K. Riedl, L. Zhang, L. Zhu, M. Huang, K. Atianzar, B. Y. Kuo, B. Gardner, R. K. Batra, et al.
Intratumoral Administration of Dendritic Cells Overexpressing CCL21 Generates Systemic Antitumor Responses and Confers Tumor Immunity
Clin. Cancer Res., April 15, 2004; 10(8): 2891 - 2901.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. Guiducci, E. Di Carlo, M. Parenza, M. Hitt, M. Giovarelli, P. Musiani, and M. P. Colombo
Intralesional Injection of Adenovirus Encoding CC Chemokine Ligand 16 Inhibits Mammary Tumor Growth and Prevents Metastatic-Induced Death after Surgical Removal of the Treated Primary Tumor
J. Immunol., April 1, 2004; 172(7): 4026 - 4036.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Gyobu, T. Tsuji, Y. Suzuki, T. Ohkuri, K. Chamoto, M. Kuroki, H. Miyoshi, Y. Kawarada, H. Katoh, T. Takeshima, et al.
Generation and Targeting of Human Tumor-Specific Tc1 and Th1 Cells Transduced with a Lentivirus Containing a Chimeric Immunoglobulin T-Cell Receptor
Cancer Res., February 15, 2004; 64(4): 1490 - 1495.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Chamoto, T. Tsuji, H. Funamoto, A. Kosaka, J. Matsuzaki, T. Sato, H. Abe, K. Fujio, K. Yamamoto, T. Kitamura, et al.
Potentiation of Tumor Eradication by Adoptive Immunotherapy with T-cell Receptor Gene-Transduced T-Helper Type 1 Cells
Cancer Res., January 1, 2004; 64(1): 386 - 390.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
O. Murillo, A. Arina, I. Tirapu, C. Alfaro, G. Mazzolini, B. Palencia, A. L.-D. De Cerio, J. Prieto, M. Bendandi, and I. Melero
Potentiation of Therapeutic Immune Responses against Malignancies with Monoclonal Antibodies
Clin. Cancer Res., November 15, 2003; 9(15): 5454 - 5464.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kobie, J. J.
Right arrow Articles by Akporiaye, E. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kobie, J. J.
Right arrow Articles by Akporiaye, E. T.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online